Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection — An observational cohort study

Toxigenic Clostridium difficile carriage in general practice: results of a laboratory-based cohort study

(2019) Frédéric Barbut et al.   CLINICAL MICROBIOLOGY AND INFECTION

Fecal Microbiota Transplantation is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection

(2019) Christian Lodberg Hvas et al.   GASTROENTEROLOGY

The effect of using Fidaxomicin on recurrent Clostridium difficile infection?

(2019) Martin Biggs et al.   JOURNAL OF HOSPITAL INFECTION

Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: A network meta-analysis

(2019) Hiroyuki Okumura et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)

(2018) L Clifford McDonald et al.   CLINICAL INFECTIOUS DISEASES

Update of treatment algorithms for Clostridium difficile infection

(2018) R.E. Ooijevaar et al.   CLINICAL MICROBIOLOGY AND INFECTION

How to: Surveillance of Clostridium difficile infections

(2018) M. Krutova et al.   CLINICAL MICROBIOLOGY AND INFECTION

Efficacy and safety of fidaxomicin for the treatment of Clostridioides ( Clostridium ) difficile infection in a randomized, double-blind, comparative Phase III study in Japan

(2018) Hiroshige Mikamo et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis

(2018) Tumas Beinortas et al.   LANCET INFECTIOUS DISEASES

Economic burden and cost-effective management of Clostridium difficile infections

(2018) S.M. Heimann et al.   MEDECINE ET MALADIES INFECTIEUSES

Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study

(2018) Chris A. Gentry et al.   CLINICAL MICROBIOLOGY AND INFECTION

A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection

(2017) Hannah E. Burton et al.   PHARMACOECONOMICS

Fidaxomicin versus Vancomycin as a First-Line Treatment for Clostridium difficile -Associated Diarrhea in Specific Patient Populations: A Pharmacoeconomic Evaluation

(2017) Kelly R. Reveles et al.   PHARMACOTHERAPY

Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France

(2017) Maureen Watt et al.   JOURNAL OF MEDICAL ECONOMICS

Clostridium difficile ribotype 176 – A predictor for high mortality and risk of nosocomial spread?

(2016) Sylvia Polivkova et al.   ANAEROBE

Enhanced surveillance ofClostridium difficileinfection occurring outside hospital, England, 2011 to 2013

(2016) Warren N Fawley et al.   Eurosurveillance

Clostridium difficile infection

(2016) Wiep Klaas Smits et al.   Nature Reviews Disease Primers

Clinical and Economic Benefits of Fidaxomicin Compared to Vancomycin for Clostridium difficile Infection

(2015) Jason C. Gallagher et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations

(2015) S. D. Goldenberg et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results From Two Multinational, Randomized, Controlled Trials

(2014) Stuart Johnson et al.   CLINICAL INFECTIOUS DISEASES

Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison

(2014) Oliver A. Cornely et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy

(2013) Mark A Miller et al.   BMC INFECTIOUS DISEASES

European Society of Clinical Microbiology and Infectious Diseases: Update of the Treatment Guidance Document for Clostridium difficile Infection

(2013) S.B. Debast et al.   CLINICAL MICROBIOLOGY AND INFECTION

Safety Analysis of Fidaxomicin in Comparison With Oral Vancomycin for Clostridium difficile Infections

(2012) K. Weiss et al.   CLINICAL INFECTIOUS DISEASES

Fidaxomicin Is an Inhibitor of the Initiation of Bacterial RNA Synthesis

(2012) Irina Artsimovitch et al.   CLINICAL INFECTIOUS DISEASES

Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin

(2012) O. A. Cornely et al.   CLINICAL INFECTIOUS DISEASES

Can we identify patients at high risk of recurrent Clostridium difficile infection?

(2012) C.P. Kelly   CLINICAL MICROBIOLOGY AND INFECTION

Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection

(2012) P.N. Wiegand et al.   JOURNAL OF HOSPITAL INFECTION

Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial

(2012) Oliver A Cornely et al.   LANCET INFECTIOUS DISEASES

Fidaxomicin: A Novel Macrocyclic Antibiotic Approved for Treatment of Clostridium difficile Infection

(2011) A. A. Venugopal et al.   CLINICAL INFECTIOUS DISEASES

Fidaxomicin versus Vancomycin forClostridium difficileInfection

(2011) Thomas J. Louie et al.   NEW ENGLAND JOURNAL OF MEDICINE

European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI)

(2009) M.P. Bauer et al.   CLINICAL MICROBIOLOGY AND INFECTION